Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Tom P. Freeman(University of Bath), H. Valerie Curran(MRC Cancer Unit), Abigail M. Freeman(University College London), Rachel Lees(University of Bath), Michael Bloomfield(University College London Hospitals NHS Foundation Trust), Celia J. A. Morgan(University of Exeter), Danica Astbury(University College London), Ali Mofeez(University College Hospital), Chandni Hindocha(University College Hospital), Jane Kinghorn(University College London), Sam Craft(New York University), Paul D. Morrison(King's College London), Emily M Thomas(University College London), Dominic O’Ryan(National Health Service), Natacha D. C. Shaban(University College London), Gianluca Baio(University College London)
Cited by 196
Related Papers
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
|Psychopharmacology|2017|969
Neural correlates of the LSD experience revealed by multimodal neuroimaging
|Proceedings of the National Academy of Sciences|2016|880
Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
|JAMA Psychiatry|2016|856
Ketamine use: a review
|Addiction|2011|638